Compounders bite 2025 outlook; still an attractive proposition
07/05/25 -"Q1 profits exceeded the street’s expectations. Nonetheless, 2025 guidance was downgraded owing to competition from compounded drugs, which, however, should evaporate in the coming quarters as ..."
Pages
72
Language
English
Published on
07/05/25
You may also be interested by these reports :
07/05/25
Q1 profits exceeded the street’s expectations. Nonetheless, 2025 guidance was downgraded owing to competition from compounded drugs, which, however, ...
06/05/25
1:10 share split adjustments – Downgrade to Add (prev.: Buy)
06/05/25
Q1 results met expectations, and strong growth was witnessed across the segments as well as three key molecules. Of note was a rebound in the animal ...
05/05/25
BioNTech’s narrative is straightforward: the company develops drugs for life-threatening illnesses and generated significant revenue by developing ...